Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia - The New England Journal of Medicine - 2018

Brief Summary:

In patients with established atherosclerotic heart disease, or diabetes and an additional risk factor, on pre-existing statin therapy with residual hypertriglyceridemia (fasting triglyceride level 135-499 mg/dL), icosapent ethyl was associated with an absolute 4.8% reduction in cardiovascular events (cardiovascular death, nonfatal MI, nonfatal stroke, coronary revascularization, or unstable angina), with a 0.9% absolute reduction in cardiovascular death, at 4.9 years.